nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—CYP1A2—chronic obstructive pulmonary disease	0.44	1	CbGaD
Anagrelide—PDE3A—Aminophylline—chronic obstructive pulmonary disease	0.386	0.898	CbGbCtD
Anagrelide—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0435	0.101	CbGbCtD
Anagrelide—CYP1A2—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.000289	0.13	CbGpPWpGaD
Anagrelide—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000195	0.00152	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000195	0.00151	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000195	0.00151	CcSEcCtD
Anagrelide—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000194	0.00151	CcSEcCtD
Anagrelide—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000194	0.00151	CcSEcCtD
Anagrelide—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000192	0.0015	CcSEcCtD
Anagrelide—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000192	0.00149	CcSEcCtD
Anagrelide—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000192	0.00149	CcSEcCtD
Anagrelide—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000192	0.00149	CcSEcCtD
Anagrelide—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000192	0.00149	CcSEcCtD
Anagrelide—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.00149	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000191	0.00148	CcSEcCtD
Anagrelide—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00019	0.00148	CcSEcCtD
Anagrelide—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.00019	0.00148	CcSEcCtD
Anagrelide—Cough—Salbutamol—chronic obstructive pulmonary disease	0.00019	0.00148	CcSEcCtD
Anagrelide—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000188	0.00146	CcSEcCtD
Anagrelide—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000188	0.00146	CcSEcCtD
Anagrelide—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000188	0.00146	CcSEcCtD
Anagrelide—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.000187	0.00146	CcSEcCtD
Anagrelide—Infection—Formoterol—chronic obstructive pulmonary disease	0.000187	0.00145	CcSEcCtD
Anagrelide—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000187	0.00145	CcSEcCtD
Anagrelide—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000185	0.00144	CcSEcCtD
Anagrelide—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000185	0.00144	CcSEcCtD
Anagrelide—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000185	0.00144	CcSEcCtD
Anagrelide—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000185	0.00144	CcSEcCtD
Anagrelide—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000184	0.00143	CcSEcCtD
Anagrelide—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000184	0.00143	CcSEcCtD
Anagrelide—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000184	0.00143	CcSEcCtD
Anagrelide—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000184	0.00143	CcSEcCtD
Anagrelide—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000183	0.00143	CcSEcCtD
Anagrelide—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000183	0.00143	CcSEcCtD
Anagrelide—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.00142	CcSEcCtD
Anagrelide—Infection—Montelukast—chronic obstructive pulmonary disease	0.000183	0.00142	CcSEcCtD
Anagrelide—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000182	0.00142	CcSEcCtD
Anagrelide—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000182	0.00142	CcSEcCtD
Anagrelide—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000181	0.00141	CcSEcCtD
Anagrelide—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00018	0.0014	CcSEcCtD
Anagrelide—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.00018	0.0014	CcSEcCtD
Anagrelide—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000179	0.00139	CcSEcCtD
Anagrelide—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.00138	CcSEcCtD
Anagrelide—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000176	0.00137	CcSEcCtD
Anagrelide—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000175	0.00137	CcSEcCtD
Anagrelide—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000175	0.00137	CcSEcCtD
Anagrelide—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000175	0.00137	CcSEcCtD
Anagrelide—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000175	0.00136	CcSEcCtD
Anagrelide—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000174	0.00136	CcSEcCtD
Anagrelide—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000174	0.00135	CcSEcCtD
Anagrelide—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.00135	CcSEcCtD
Anagrelide—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000172	0.00134	CcSEcCtD
Anagrelide—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000171	0.00133	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000171	0.00133	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000171	0.00133	CcSEcCtD
Anagrelide—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.00132	CcSEcCtD
Anagrelide—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00017	0.00132	CcSEcCtD
Anagrelide—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000169	0.00132	CcSEcCtD
Anagrelide—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000169	0.00131	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000168	0.0013	CcSEcCtD
Anagrelide—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000167	0.0013	CcSEcCtD
Anagrelide—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000167	0.0013	CcSEcCtD
Anagrelide—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000167	0.0013	CcSEcCtD
Anagrelide—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000167	0.0013	CcSEcCtD
Anagrelide—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000166	0.0013	CcSEcCtD
Anagrelide—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000166	0.00129	CcSEcCtD
Anagrelide—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000166	0.00129	CcSEcCtD
Anagrelide—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000165	0.00129	CcSEcCtD
Anagrelide—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000165	0.00129	CcSEcCtD
Anagrelide—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000165	0.00129	CcSEcCtD
Anagrelide—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000165	0.00128	CcSEcCtD
Anagrelide—Injury—Prednisone—chronic obstructive pulmonary disease	0.000164	0.00127	CcSEcCtD
Anagrelide—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000164	0.00127	CcSEcCtD
Anagrelide—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000163	0.00127	CcSEcCtD
Anagrelide—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000163	0.00127	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000162	0.00126	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.00126	CcSEcCtD
Anagrelide—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000162	0.00126	CcSEcCtD
Anagrelide—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.00126	CcSEcCtD
Anagrelide—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000162	0.00126	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000162	0.00126	CcSEcCtD
Anagrelide—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.00125	CcSEcCtD
Anagrelide—Pain—Formoterol—chronic obstructive pulmonary disease	0.000161	0.00125	CcSEcCtD
Anagrelide—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.00125	CcSEcCtD
Anagrelide—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000161	0.00125	CcSEcCtD
Anagrelide—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00016	0.00125	CcSEcCtD
Anagrelide—Amnesia—Prednisone—chronic obstructive pulmonary disease	0.00016	0.00125	CcSEcCtD
Anagrelide—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.00124	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000159	0.00124	CcSEcCtD
Anagrelide—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000159	0.00123	CcSEcCtD
Anagrelide—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000158	0.00123	CcSEcCtD
Anagrelide—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000158	0.00123	CcSEcCtD
Anagrelide—Pain—Montelukast—chronic obstructive pulmonary disease	0.000157	0.00122	CcSEcCtD
Anagrelide—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000157	0.00122	CcSEcCtD
Anagrelide—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000157	0.00122	CcSEcCtD
Anagrelide—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.00122	CcSEcCtD
Anagrelide—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000156	0.00122	CcSEcCtD
Anagrelide—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000156	0.00121	CcSEcCtD
Anagrelide—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000155	0.00121	CcSEcCtD
Anagrelide—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000155	0.00121	CcSEcCtD
Anagrelide—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000155	0.00121	CcSEcCtD
Anagrelide—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000155	0.00121	CcSEcCtD
Anagrelide—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000155	0.0012	CcSEcCtD
Anagrelide—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000154	0.0012	CcSEcCtD
Anagrelide—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000154	0.0012	CcSEcCtD
Anagrelide—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000154	0.0012	CcSEcCtD
Anagrelide—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000154	0.0012	CcSEcCtD
Anagrelide—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000154	0.0012	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.00119	CcSEcCtD
Anagrelide—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.00119	CcSEcCtD
Anagrelide—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.00118	CcSEcCtD
Anagrelide—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.00118	CcSEcCtD
Anagrelide—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00015	0.00117	CcSEcCtD
Anagrelide—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.00015	0.00117	CcSEcCtD
Anagrelide—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.00015	0.00117	CcSEcCtD
Anagrelide—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000149	0.00116	CcSEcCtD
Anagrelide—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000149	0.00116	CcSEcCtD
Anagrelide—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000148	0.00116	CcSEcCtD
Anagrelide—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000148	0.00116	CcSEcCtD
Anagrelide—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000148	0.00116	CcSEcCtD
Anagrelide—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000148	0.00116	CcSEcCtD
Anagrelide—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000148	0.00115	CcSEcCtD
Anagrelide—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000147	0.00114	CcSEcCtD
Anagrelide—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000147	0.00114	CcSEcCtD
Anagrelide—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000147	0.00114	CcSEcCtD
Anagrelide—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000146	0.00114	CcSEcCtD
Anagrelide—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000146	0.00114	CcSEcCtD
Anagrelide—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000146	0.00114	CcSEcCtD
Anagrelide—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000145	0.00113	CcSEcCtD
Anagrelide—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000145	0.00113	CcSEcCtD
Anagrelide—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000145	0.00113	CcSEcCtD
Anagrelide—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000144	0.00112	CcSEcCtD
Anagrelide—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000143	0.00111	CcSEcCtD
Anagrelide—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.0011	CcSEcCtD
Anagrelide—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00014	0.00109	CcSEcCtD
Anagrelide—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00014	0.00109	CcSEcCtD
Anagrelide—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000138	0.00108	CcSEcCtD
Anagrelide—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000138	0.00107	CcSEcCtD
Anagrelide—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000138	0.00107	CcSEcCtD
Anagrelide—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000135	0.00105	CcSEcCtD
Anagrelide—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000135	0.00105	CcSEcCtD
Anagrelide—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000133	0.00103	CcSEcCtD
Anagrelide—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000133	0.00103	CcSEcCtD
Anagrelide—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000132	0.00103	CcSEcCtD
Anagrelide—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00013	0.00101	CcSEcCtD
Anagrelide—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000128	0.001	CcSEcCtD
Anagrelide—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000128	0.001	CcSEcCtD
Anagrelide—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000128	0.000996	CcSEcCtD
Anagrelide—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000992	CcSEcCtD
Anagrelide—PDE3A—Nitric oxide stimulates guanylate cyclase—NOS2—chronic obstructive pulmonary disease	0.000127	0.0572	CbGpPWpGaD
Anagrelide—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.000991	CcSEcCtD
Anagrelide—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000126	0.00098	CcSEcCtD
Anagrelide—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000125	0.000977	CcSEcCtD
Anagrelide—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000124	0.000967	CcSEcCtD
Anagrelide—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000124	0.000967	CcSEcCtD
Anagrelide—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000122	0.000947	CcSEcCtD
Anagrelide—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.000945	CcSEcCtD
Anagrelide—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000932	CcSEcCtD
Anagrelide—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000119	0.00093	CcSEcCtD
Anagrelide—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000119	0.00093	CcSEcCtD
Anagrelide—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000118	0.000922	CcSEcCtD
Anagrelide—Rash—Formoterol—chronic obstructive pulmonary disease	0.000118	0.000922	CcSEcCtD
Anagrelide—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000118	0.000921	CcSEcCtD
Anagrelide—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000118	0.000921	CcSEcCtD
Anagrelide—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000921	CcSEcCtD
Anagrelide—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000118	0.000916	CcSEcCtD
Anagrelide—Headache—Formoterol—chronic obstructive pulmonary disease	0.000118	0.000916	CcSEcCtD
Anagrelide—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000916	CcSEcCtD
Anagrelide—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.000915	CcSEcCtD
Anagrelide—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000117	0.000913	CcSEcCtD
Anagrelide—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000117	0.000911	CcSEcCtD
Anagrelide—Rash—Montelukast—chronic obstructive pulmonary disease	0.000116	0.000903	CcSEcCtD
Anagrelide—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000116	0.000902	CcSEcCtD
Anagrelide—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000116	0.0009	CcSEcCtD
Anagrelide—Depression—Prednisone—chronic obstructive pulmonary disease	0.000116	0.0009	CcSEcCtD
Anagrelide—Headache—Montelukast—chronic obstructive pulmonary disease	0.000115	0.000897	CcSEcCtD
Anagrelide—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000114	0.00089	CcSEcCtD
Anagrelide—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000884	CcSEcCtD
Anagrelide—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000113	0.000878	CcSEcCtD
Anagrelide—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000112	0.000875	CcSEcCtD
Anagrelide—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000112	0.000871	CcSEcCtD
Anagrelide—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000112	0.00087	CcSEcCtD
Anagrelide—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000112	0.00087	CcSEcCtD
Anagrelide—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000112	0.000869	CcSEcCtD
Anagrelide—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000112	0.000869	CcSEcCtD
Anagrelide—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000111	0.000865	CcSEcCtD
Anagrelide—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.00011	0.000853	CcSEcCtD
Anagrelide—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000109	0.000851	CcSEcCtD
Anagrelide—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000108	0.000841	CcSEcCtD
Anagrelide—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000108	0.000838	CcSEcCtD
Anagrelide—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000105	0.00082	CcSEcCtD
Anagrelide—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000105	0.000816	CcSEcCtD
Anagrelide—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000814	CcSEcCtD
Anagrelide—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000104	0.00081	CcSEcCtD
Anagrelide—PDE3A—Nitric oxide stimulates guanylate cyclase—NOS3—chronic obstructive pulmonary disease	0.000102	0.046	CbGpPWpGaD
Anagrelide—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000796	CcSEcCtD
Anagrelide—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.000792	CcSEcCtD
Anagrelide—Shock—Prednisolone—chronic obstructive pulmonary disease	0.0001	0.000779	CcSEcCtD
Anagrelide—PDE3A—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	0.0001	0.0449	CbGpPWpGaD
Anagrelide—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	9.93e-05	0.000773	CcSEcCtD
Anagrelide—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	9.83e-05	0.000766	CcSEcCtD
Anagrelide—Eye disorder—Prednisone—chronic obstructive pulmonary disease	9.72e-05	0.000757	CcSEcCtD
Anagrelide—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	9.29e-05	0.000724	CcSEcCtD
Anagrelide—Insomnia—Prednisolone—chronic obstructive pulmonary disease	9.2e-05	0.000716	CcSEcCtD
Anagrelide—Alopecia—Prednisone—chronic obstructive pulmonary disease	9.19e-05	0.000716	CcSEcCtD
Anagrelide—CYP1A2—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	9.18e-05	0.0412	CbGpPWpGaD
Anagrelide—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	9.13e-05	0.000711	CcSEcCtD
Anagrelide—Malnutrition—Prednisone—chronic obstructive pulmonary disease	9.06e-05	0.000705	CcSEcCtD
Anagrelide—Pain—Prednisolone—chronic obstructive pulmonary disease	8.7e-05	0.000677	CcSEcCtD
Anagrelide—Vision blurred—Prednisone—chronic obstructive pulmonary disease	8.53e-05	0.000665	CcSEcCtD
Anagrelide—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	8.4e-05	0.000654	CcSEcCtD
Anagrelide—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	8.38e-05	0.000653	CcSEcCtD
Anagrelide—Anaemia—Prednisone—chronic obstructive pulmonary disease	8.37e-05	0.000652	CcSEcCtD
Anagrelide—Malaise—Prednisone—chronic obstructive pulmonary disease	8.17e-05	0.000636	CcSEcCtD
Anagrelide—Syncope—Prednisone—chronic obstructive pulmonary disease	8.12e-05	0.000632	CcSEcCtD
Anagrelide—Urticaria—Prednisolone—chronic obstructive pulmonary disease	8.08e-05	0.000629	CcSEcCtD
Anagrelide—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	7.96e-05	0.00062	CcSEcCtD
Anagrelide—Convulsion—Prednisone—chronic obstructive pulmonary disease	7.85e-05	0.000611	CcSEcCtD
Anagrelide—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	7.82e-05	0.0351	CbGpPWpGaD
Anagrelide—Hypertension—Prednisone—chronic obstructive pulmonary disease	7.82e-05	0.000609	CcSEcCtD
Anagrelide—Arthralgia—Prednisone—chronic obstructive pulmonary disease	7.71e-05	0.0006	CcSEcCtD
Anagrelide—Myalgia—Prednisone—chronic obstructive pulmonary disease	7.71e-05	0.0006	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	7.66e-05	0.000596	CcSEcCtD
Anagrelide—Discomfort—Prednisone—chronic obstructive pulmonary disease	7.62e-05	0.000593	CcSEcCtD
Anagrelide—Oedema—Prednisone—chronic obstructive pulmonary disease	7.39e-05	0.000575	CcSEcCtD
Anagrelide—Infection—Prednisone—chronic obstructive pulmonary disease	7.34e-05	0.000572	CcSEcCtD
Anagrelide—Shock—Prednisone—chronic obstructive pulmonary disease	7.27e-05	0.000566	CcSEcCtD
Anagrelide—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	7.25e-05	0.000564	CcSEcCtD
Anagrelide—Tachycardia—Prednisone—chronic obstructive pulmonary disease	7.21e-05	0.000562	CcSEcCtD
Anagrelide—Skin disorder—Prednisone—chronic obstructive pulmonary disease	7.18e-05	0.000559	CcSEcCtD
Anagrelide—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	7.14e-05	0.000556	CcSEcCtD
Anagrelide—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	7.12e-05	0.032	CbGpPWpGaD
Anagrelide—Anorexia—Prednisone—chronic obstructive pulmonary disease	7.05e-05	0.000549	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	6.73e-05	0.000524	CcSEcCtD
Anagrelide—Dizziness—Prednisolone—chronic obstructive pulmonary disease	6.73e-05	0.000524	CcSEcCtD
Anagrelide—Insomnia—Prednisone—chronic obstructive pulmonary disease	6.68e-05	0.000521	CcSEcCtD
Anagrelide—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	6.64e-05	0.000517	CcSEcCtD
Anagrelide—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	6.51e-05	0.000507	CcSEcCtD
Anagrelide—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	6.42e-05	0.0005	CcSEcCtD
Anagrelide—Rash—Prednisolone—chronic obstructive pulmonary disease	6.41e-05	0.000499	CcSEcCtD
Anagrelide—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	6.41e-05	0.000499	CcSEcCtD
Anagrelide—Fatigue—Prednisone—chronic obstructive pulmonary disease	6.37e-05	0.000496	CcSEcCtD
Anagrelide—Headache—Prednisolone—chronic obstructive pulmonary disease	6.37e-05	0.000496	CcSEcCtD
Anagrelide—Constipation—Prednisone—chronic obstructive pulmonary disease	6.32e-05	0.000492	CcSEcCtD
Anagrelide—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	6.09e-05	0.000474	CcSEcCtD
Anagrelide—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	6.04e-05	0.000471	CcSEcCtD
Anagrelide—Nausea—Prednisolone—chronic obstructive pulmonary disease	6.04e-05	0.00047	CcSEcCtD
Anagrelide—Urticaria—Prednisone—chronic obstructive pulmonary disease	5.87e-05	0.000457	CcSEcCtD
Anagrelide—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	5.84e-05	0.000455	CcSEcCtD
Anagrelide—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	5.84e-05	0.000455	CcSEcCtD
Anagrelide—CYP1A2—Estrogen Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	5.31e-05	0.0238	CbGpPWpGaD
Anagrelide—Asthenia—Prednisone—chronic obstructive pulmonary disease	5.3e-05	0.000413	CcSEcCtD
Anagrelide—Pruritus—Prednisone—chronic obstructive pulmonary disease	5.23e-05	0.000407	CcSEcCtD
Anagrelide—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	5.06e-05	0.000394	CcSEcCtD
Anagrelide—PDE3A—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	5.06e-05	0.0227	CbGpPWpGaD
Anagrelide—PDE3A—Platelet homeostasis—NOS2—chronic obstructive pulmonary disease	4.96e-05	0.0223	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SERPINE2—chronic obstructive pulmonary disease	4.9e-05	0.022	CbGpPWpGaD
Anagrelide—Dizziness—Prednisone—chronic obstructive pulmonary disease	4.89e-05	0.000381	CcSEcCtD
Anagrelide—Vomiting—Prednisone—chronic obstructive pulmonary disease	4.7e-05	0.000366	CcSEcCtD
Anagrelide—Rash—Prednisone—chronic obstructive pulmonary disease	4.66e-05	0.000363	CcSEcCtD
Anagrelide—Dermatitis—Prednisone—chronic obstructive pulmonary disease	4.66e-05	0.000363	CcSEcCtD
Anagrelide—Headache—Prednisone—chronic obstructive pulmonary disease	4.63e-05	0.000361	CcSEcCtD
Anagrelide—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	4.49e-05	0.0202	CbGpPWpGaD
Anagrelide—Nausea—Prednisone—chronic obstructive pulmonary disease	4.39e-05	0.000342	CcSEcCtD
Anagrelide—CYP1A2—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	4.31e-05	0.0194	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	4.28e-05	0.0192	CbGpPWpGaD
Anagrelide—CYP1A2—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	4.09e-05	0.0184	CbGpPWpGaD
Anagrelide—PDE3A—Platelet homeostasis—NOS3—chronic obstructive pulmonary disease	3.99e-05	0.0179	CbGpPWpGaD
Anagrelide—CYP1A2—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	3.76e-05	0.0169	CbGpPWpGaD
Anagrelide—CYP1A2—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	3.62e-05	0.0162	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	3.16e-05	0.0142	CbGpPWpGaD
Anagrelide—CYP1A2—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	2.98e-05	0.0134	CbGpPWpGaD
Anagrelide—CYP1A2—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	2.79e-05	0.0125	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	2.46e-05	0.011	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	2.4e-05	0.0108	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	2.2e-05	0.00987	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TGFB2—chronic obstructive pulmonary disease	2.13e-05	0.00958	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	2.05e-05	0.00921	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	1.93e-05	0.00867	CbGpPWpGaD
Anagrelide—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	1.93e-05	0.00867	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	1.93e-05	0.00867	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—HDAC2—chronic obstructive pulmonary disease	1.91e-05	0.00859	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	1.9e-05	0.00855	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	1.88e-05	0.00845	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	1.86e-05	0.00837	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	1.81e-05	0.00811	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PLAUR—chronic obstructive pulmonary disease	1.73e-05	0.00775	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	1.65e-05	0.00743	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	1.56e-05	0.00701	CbGpPWpGaD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	1.54e-05	0.00692	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	1.5e-05	0.00674	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	1.45e-05	0.00652	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	1.32e-05	0.00592	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	1.27e-05	0.00568	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—MMP1—chronic obstructive pulmonary disease	1.23e-05	0.00554	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	1.21e-05	0.00544	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PLAU—chronic obstructive pulmonary disease	1.21e-05	0.00544	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	1.11e-05	0.005	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NOS2—chronic obstructive pulmonary disease	1.11e-05	0.00499	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.1e-05	0.00494	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	1.1e-05	0.00494	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	1.07e-05	0.0048	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.04e-05	0.00466	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	9.42e-06	0.00423	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	9.36e-06	0.0042	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ALB—chronic obstructive pulmonary disease	9.34e-06	0.0042	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	9.27e-06	0.00416	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	9.04e-06	0.00406	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NOS3—chronic obstructive pulmonary disease	8.94e-06	0.00401	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	8.87e-06	0.00398	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	8.42e-06	0.00378	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	8.3e-06	0.00373	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	8.14e-06	0.00366	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	8.14e-06	0.00366	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	8.11e-06	0.00364	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	7.83e-06	0.00351	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	7.75e-06	0.00348	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	7.75e-06	0.00348	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.72e-06	0.00347	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.61e-06	0.00342	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	7.36e-06	0.00331	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	7.09e-06	0.00318	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	6.99e-06	0.00314	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.72e-06	0.00302	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.63e-06	0.00298	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	6.49e-06	0.00291	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—VEGFA—chronic obstructive pulmonary disease	6.44e-06	0.00289	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KL—chronic obstructive pulmonary disease	6.03e-06	0.00271	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TGFB1—chronic obstructive pulmonary disease	5.91e-06	0.00265	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	5.57e-06	0.0025	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	5.41e-06	0.00243	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	5.01e-06	0.00225	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.97e-06	0.00223	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TP53—chronic obstructive pulmonary disease	4.87e-06	0.00219	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	4.55e-06	0.00204	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	4.52e-06	0.00203	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.35e-06	0.00195	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.04e-06	0.00182	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.86e-06	0.00173	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.58e-06	0.00161	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	3.48e-06	0.00157	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.33e-06	0.00149	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.24e-06	0.00146	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.17e-06	0.00143	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.03e-06	0.00136	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.69e-06	0.00121	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.58e-06	0.00116	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.56e-06	0.00115	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.43e-06	0.00109	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.18e-06	0.00098	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2e-06	0.0009	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.96e-06	0.000882	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.9e-06	0.000855	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.88e-06	0.000845	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.75e-06	0.000788	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	1.72e-06	0.000771	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.65e-06	0.000741	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.51e-06	0.000678	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.32e-06	0.000593	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.3e-06	0.000584	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.21e-06	0.000545	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.15e-06	0.000516	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	7.81e-07	0.000351	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	7.47e-07	0.000336	CbGpPWpGaD
